Stock Events

Halozyme Therapeutics 

$53.91
43
+$0+0% Today

Statistics

Day High
53.91
Day Low
52.77
52W High
-
52W Low
-
Volume
520
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.47
0.59
0.7
0.82
Expected EPS
0.69
Actual EPS
0.79

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0J2O.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals competes in the biotech space, focusing on innovative biologic medicines, overlapping with Halozyme's therapeutic areas.
AMGEN
AMGN
Mkt Cap177.47B
Amgen is a biopharmaceutical company that develops and produces medicines, including treatments in areas that Halozyme targets, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, competing with Halozyme in the biotech innovation space.
Biogen
BIIB
Mkt Cap33.5B
Biogen competes with Halozyme in the development of therapies for neurological and neurodegenerative diseases, among other areas.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences is a research-based biopharmaceutical company that develops drugs in areas that overlap with Halozyme's therapeutic targets.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie operates in similar therapeutic areas as Halozyme, including immunology and oncology, making them competitors in the biopharmaceutical field.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals in competitive areas with Halozyme, including cancer treatments.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a global biopharmaceutical company with a wide range of products that compete across several of Halozyme's key therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a global biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines that compete with Halozyme's portfolio.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca is a global, science-led biopharmaceutical business that operates in similar therapeutic areas as Halozyme, including oncology and immunotherapy.

About

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Show more...
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Employees
145
Country
United States
ISIN
US40637H1095
WKN
000A0DLHS

Listings